FAPα Antibody (SS-13): sc-100528

FAPα Antibody (SS-13) is a mouse monoclonal IgG2a kappa light chain antibody that detects FAP alpha protein of human origin by western blotting (WB), immunoprecipitation (IP), and enzyme-linked immunosorbent assay (ELISA). Anti-FAP alpha antibody (SS-13) is available as a non-conjugated format. FAPα, also known as Seprase, is a 760 amino acid protein encoded by the human gene FAP and is a member of the peptidase S9B family. FAP alpha (SS-13) antibody targets a protein that plays a crucial role in tissue remodeling, particularly during development and wound healing, which is significant as FAP alpha may contribute to the invasiveness of malignant cancers. FAPα is known to degrade gelatin and heat-denatured type I and type IV collagen, although FAPα does not cleave native type I or type IV collagen, laminin, fibronectin, fibrin, or casein. FAPα is a single-pass type II membrane protein located on cell surface lamellipodia, invadopodia, and shed vesicles, where FAPα is typically found as a glycosylated homodimer or heterodimer with DPP4. The monomeric form of FAPα is inactive, highlighting the importance of dimerization for functional activity. This unique structural characteristic underscores FAPα′s role in facilitating interactions with other proteins and potential implications in cancer biology.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

FAPα Antibody (SS-13) References:

1. Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein alpha.  |  Aertgeerts, K., et al. 2005. J Biol Chem. 280: 19441-4. PMID: 15809306
2. Fibroblast activation protein-alpha and dipeptidyl peptidase IV (CD26): cell-surface proteases that activate cell signaling and are potential targets for cancer therapy.  |  Kelly, T. 2005. Drug Resist Updat. 8: 51-8. PMID: 15939342
3. Characterization of cancer stroma markers: in silico analysis of an mRNA expression database for fibroblast activation protein and endosialin.  |  Dolznig, H., et al. 2005. Cancer Immun. 5: 10. PMID: 16076089
4. 'Increased expression of seprase, a membrane-type serine protease, is associated with lymph node metastasis in human colorectal cancer'.  |  Iwasa, S., et al. 2005. Cancer Lett. 227: 229-36. PMID: 16196122
5. Fibroblast activation protein alpha is expressed by chondrocytes following a pro-inflammatory stimulus and is elevated in osteoarthritis.  |  Milner, JM., et al. 2006. Arthritis Res Ther. 8: R23. PMID: 16507127
6. Dipeptide proline diphenyl phosphonates are potent, irreversible inhibitors of seprase (FAPalpha).  |  Gilmore, BF., et al. 2006. Biochem Biophys Res Commun. 346: 436-46. PMID: 16769036
7. Meiosis: separase strikes twice.  |  Terret, ME. and Jallepalli, PV. 2006. Nat Cell Biol. 8: 910-1. PMID: 16946739
8. Expression of seprase in effusions from patients with epithelial ovarian carcinoma.  |  Zhang, MZ., et al. 2007. Chin Med J (Engl). 120: 663-8. PMID: 17517181
9. Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors.  |  Koyama, T., et al. 2024. Cancer Res Commun. 4: 2349-2358. PMID: 39140264
10. Enzymatic activity of fibroblast activation protein-α is essential for TGF-β1-induced fibroblastic differentiation of human periodontal ligament cells.  |  Kim, SM. and Jang, YJ. 2024. Exp Cell Res. 442: 114230. PMID: 39222867
11. Efficient α and β- radionuclide therapy targeting fibroblast activation protein-α in an aggressive preclinical mouse tumour model.  |  Ceuppens, H., et al. 2024. Eur J Nucl Med Mol Imaging.. PMID: 39237746
12. FAP-α is an effective tool to evaluate stroma invasion of lung adenocarcinoma.  |  Xiong, S., et al. 2024. Diagn Pathol. 19: 152. PMID: 39587644

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-FAPα Antibody (SS-13) has 11 citations in a variety of scientific publications.

Primary antibodies like Anti-FAPα Antibody (SS-13) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

FAPα Antibody (SS-13) Specifications

Alternate Product Name: FAPα

Product Clone Name: SS-13

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2a kappa light chain

Amino Acids: 525-625

Epitope Target: FAPα

Epitope Species: human

Product Reactivity/Detection: FAPα

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, ELISA

Vialing Information: Each vial contains 100 µg IgG_2a kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 11 citations in various scientific publications

Available Conjugates/Forms for FAPα Antibody (SS-13): N/A